Clinical Trials Directory

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

In this study, people will get a special Medtronic pacemaker placed in their chest. This pacemaker uses special settings to test whether a pacing rate based on each person’s body and heart helps improve heart failure symptoms. After the device is placed, people are put into one of two groups by chance. One group gets personalized pacing based on their height and heart function. The other group gets very little pacing, used only as a backup if the heart rate drops too low. Most people and study staff will not know which group they are in during the first year so the results stay fair. People will return for checkups at 2, 6, 12, 14, 18, and 24 months, and then once a year. At these visits, they may have heart images, blood tests, ECGs, questionnaires, a six minute walk test, and pacemaker checks. After the 12 month visit, everyone in the group with minimal pacing will switch to personalized pacing, and the study will continue to check safety and benefits.

People in the study will get meals delivered to their homes from local groups. They’ll also agree to share what the experience was like for them.

We are doing this study to find out if an investigational drug called teclistamab (the study drug) is a safe and effective option for people who have multiple myeloma and have achieved at least a partial response to standard therapy. We want to know how well it works on its own and in combination with a standard drug called lenalidomide.